Clinical trial · Observational
Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy
Prospectively Predict the Efficacy of Precise Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy
NCT05334849CI-TRIAL-00061417completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To vertify the function of circulating exosomal lncRNA-GC1 on predicting and monitoring immunotherapeutic outcomes of GC
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Gastric Carcinoma | Gastric Carcinoma | CURATED_BROADER | 0.78 |
| Immunotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Circulating exosomal lncRNA-GC1 detection | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Levels of circulating exosomal lncRNA-GC1
- timeFrame
- Circulating exosomal lncRNA-GC1 was detected, analysis and reported at the baseline
- description
- Circulating exosomal lncRNA-GC1 was detected by the RT-PCR followed by isolating exosomes.
- measure
- Levels of circulating exosomal lncRNA-GC1
- timeFrame
- Circulating exosomal lncRNA-GC1 was detected, analysis and reported through study completion, average 1 year
- description
- Circulating exosomal lncRNA-GC1 was detected by the RT-PCR followed by isolating exosomes.
Secondary outcomes (1)
- measure
- Survival outcomes of circulating exosomal lncRNA-GC1
- timeFrame
- up to 3 years
- description
- Analysis participants' survival with different levels of circulating exosomal lncRNA-GC1 detected by RT-PCR.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Having signed informed consent * Age≥ 18 years old * Histologically confirmed gastric adenocarcinoma * Unresectable recurrent or metastatic disease * Measurable disease according to the RECIST criteria * Life expectancy of ≥3 month * No prior chemotherapy of the study more than 4 weeks * Immunotherapy regimens were included in the treatment Exclusion Criteria: * Other previous malignancy within 5 year * Surgery (excluding diagnostic biopsy) within 4 weeks prior to study * Pregnancy or lactation period * Legal incapacity
References
Publications (0)
Data not yet available
No reference posted for this study.